<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052256</url>
  </required_header>
  <id_info>
    <org_study_id>THRONE1</org_study_id>
    <nct_id>NCT04052256</nct_id>
  </id_info>
  <brief_title>The Heartflow Coronary Disease Progression Evaluation Study</brief_title>
  <acronym>THRONE</acronym>
  <official_title>The Heartflow Coronary Disease Progression Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasively measured fractional flow reserve (FFR) has proven to be useful in guiding coronary
      revascularization. Several studies have shown that it is justified to treat lesions with a
      value of 0.80 or lower and safe to defer from PCI in lesions with a value of &gt;0.80. Recently,
      computational fluid dynamics have allowed FFR measurement from coronary computed tomography
      angiography images (FFRCT) with excellent diagnostic accuracy compared to invasive FFR.

      FFRCT can also effectively guide revascularization safely deferring patient with FFRCT &gt;0.80
      from invasive angiography. In functionally non-significant lesions, computational fluid
      dynamic models in addition to CT plaque characteristics (low attenuation, positive
      remodelling, spotty calcification and napkin-ring sign) may be able to predict which lesions
      will become flow-limiting, causing clinical events in the future.

      This study will evaluate disease progression in intermediate lesions (invasive FFR 0.81-0.90
      at baseline) using FFRCT at 2 years and determine whether CT characteristics may help to
      identify lesions that are more susceptible for FFR decline. Additionally, we will correlate
      CT characteristics with coronary events (a composite endpoint consisting of all-cause
      mortality, target-vessel myocardial infarction and clinically driven target-vessel
      revascularization) up to 5 years after the baseline invasive FFR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary atherosclerotic disease progression</measure>
    <time_frame>2 years</time_frame>
    <description>FFRCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure Target vessel failure</measure>
    <time_frame>3-5 years</time_frame>
    <description>Composite of all-cause mortality, target-vessel myocardial infarction and cinically driven target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularisation</measure>
    <time_frame>3-5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Patients with intermediate coronary lesions</arm_group_label>
    <description>Patients (age ≥ 18 years) who have undergone invasive coronary angiography and have a minimum of one non-treated coronary artery with a measured invasive FFR of 0.81-0.90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary computed tomography angiography</intervention_name>
    <description>Computational fluid dynamic model information derived from CT</description>
    <arm_group_label>Patients with intermediate coronary lesions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients (age ≥ 18 years) treated with PCI (for non-ST elevation myocardial infarction,
        unstable or stable angina and silent ischemia) or who undergo invasive FFR.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients (age ≥ 18 years) treated with PCI (for non-ST elevation myocardial
             infarction, unstable or stable angina and silent ischemia) or who undergo invasive
             FFR.

          2. Minimum of one non-treated coronary artery with an intermediate lesion and invasive
             FFR 0.81-0.90 to serve as the target vessel for FFRCT.

        Exclusion Criteria:

          1. ST elevation myocardial infarction.

          2. Previous CABG.

          3. Target vessel for FFR measurement &lt; 2.0 mm in diameter.

          4. Contraindications to contrast agents, beta-blocking agents, nitroglycerin or
             adenosine.

          5. Life expectancy less than 3 years.

          6. Creatinine clearance &lt; 30 ml/min*1.73m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Leipsic, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas van Mieghem, MD, PhD</last_name>
    <phone>00311070438894</phone>
    <email>n.vanmieghem@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Admir Dedic, MD, PhD</last_name>
    <phone>00311070438894</phone>
    <email>a.dedic@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Admir Dedic, MD, PhD</last_name>
      <phone>00311070438894</phone>
      <email>a.dedic@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Nicolas van Mieghem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Admir Dedic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>Director of Interventional Cardiology</investigator_title>
  </responsible_party>
  <keyword>Fractional flow reserve</keyword>
  <keyword>Coronary computed tomography angiography</keyword>
  <keyword>Computational fluid dynamics</keyword>
  <keyword>Plaque characteristics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

